IV Fluid Plant in Florida Remains Functional After Milton

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 11, 2024.

By Ernie Mundell HealthDay Reporter

FRIDAY, Oct. 11, 2024 -- Facing a nationwide shortage of vital IV fluids after Hurricane Helene knocked out a North Carolina production plant, officials heaved a sigh of relief at the news that a second plant in Daytona Beach, Fla., was spared by Hurricane Milton and remains functional.

According to the New York Times, a spokeswoman for B. Braun, the company that runs the Daytona Beach plant, said the facility remained intact and would reopen on Friday.

Between them, the North Carolina and Florida plants produce 60% and 25%, respectively, of the IV fluids that many patients in hospitals and dialysis centers need to survive.

With supplies already crippled by the closure of Baxter's Marion, NC, plant after Helene, the closure of the B. Braun facility would have been devastating, experts said.

IV fluids are needed for the care of patients such as premature babies, people on dialysis and frail individuals who rely on IV feeding.

Hospitals across the United States are already postponing surgeries and rationing IV fluids as shortages take hold, the Times said.

Hannah Hale, 37, lives near Dallas and for eight years has required IV feeding with a concentrated dextrose solution, after Crohn's disease led to surgeries that impaired her digestive tract.

Her specialized pharmacy told her on Monday it cannot find enough of the IV solution to replenish her supply.

“They’re not supposed to just drop me like that,” she told the Times, adding that calls to 14 other pharmacies failed to find a new supplier.

“I don’t have any recourse," Hale said.

Anticipating Milton, B. Braun had told the Times that on Tuesday it had loaded trucks headed north full of products, to get them to a safer location.

At Baxter, staff have been working overtime to help patch together new supply chains, increasing production at plants located overseas.

On Wednesday, the U.S. Food and Drug Administration (FDA) said that it was authorizing imports of IV products from Baxter plants in Canada, Ireland, the United Kingdom and China.

Baxter had been forced to limit supplies to hospitals to 40% of usual following the damage to its plant by Helene, but the company told the Times that deliveries would have already risen to about 60% of usual by Wednesday of this week.

Baxter would not say when it expected its Marion plant to become fully operational again, but said it hoped to resume production in phases by the end of the year.

A bridge near the plant is being prioritized for repair so that trucks already loaded with Baxter product can leave and distribute supplies not damaged by the storm, the Times said.

“We will spare no resource -- human or financial -- to restart operations and help ensure patients and providers have the products they need,” José Almeida, the chief executive at Baxter, said in a statement Wednesday.

Hospitals across the nation need IV fluids to hydrate and feed patients, including those battling a life-threatening blood infection known as sepsis.

“When you’re coming in with sepsis, and specifically the septic shock, those one-liter bags are the most immediate form of treatments, and sometimes you’re getting two, if not three, of them in rapid succession,” Dr. Chris DeRienzo, chief physician executive of the American Hospital Association, explained to the Times. “There are so many special populations impacted by the shortage, what it really leads to is an impact on the whole population.”

IV fluids made by Baxter and B. Braun are also essential to the care of people in dialysis, because patients need specially formulated liquids to help clean their blood once kidneys begin to fail.

The Marion plant was a major supplier of such fluids, William Poirier of the Renal Healthcare Association told the Times.

Responding to the crisis, Xavier Becerra, secretary of the Health and Human Services Department, said in a letter to health care providers posted Wednesday that his agency was doing all it can. HHS was working with Baxter closely to help minimize disruptions in supply, he said.

“My department commits to mitigating the impact of Hurricane Helene and doing all we can to prevent further disruption as a result of Hurricane Milton,” the letter from Becerra said.

The suddenness of the IV fluid crisis highlights ongoing concerns about the fragility of the supply chain of essential medical supplies in the United States. Experts have long noted that the manufacture and distribution of certain items is concentrated in only a few companies.

The COVID pandemic revealed many vulnerabilities, as officials scrambled to find essential supplies of masks, gloves and ventilators. In 2023, tornado damage to a Pfizer plant in North Carolina sparked a frenzied search for new supplies of certain generic drugs.

Most of the products involved in these shortages are low-cost, low-profit items with few incentives for new manufacturers to enter into production, experts explained.

Whether government is doing enough to build capacity is uncertain, Tom Cotter, executive director of Healthcare Ready, a nonprofit founded after Hurricane Katrina, told the Times.

“We haven’t seen a really big uptick in investment in resiliency from the government to harden our supply chains,” Cotter said. “Storms are reaching areas where they’ve never been before with greater severity. There is an increased need to widen the scope of what we think is vulnerable in our medical supply chain.”

Sources

  • Statements, Baxter International, U.S. Department of Health and Human Services and the U.S. Food and Drug Administration
  • The New York Times

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-10-12 00:00

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords